Kvetny J, Frederikesen P K, Jacobsen J G, Haas V, Feldt-Rasmussen U, Date J
Acta Med Scand. 1981;209(5):389-92. doi: 10.1111/j.0954-6820.1981.tb11613.x.
Twenty-five patients with newly diagnosed thyrotoxicosis participated in a double-blind study of the added effect of propranolol during tiamazol treatment. During the trial, the effect of treatment was ascertained by estimation at regular intervals of the clinical score (Crooks-Wayne index), free thyroxine index, serum triiodothyronine, serum reverse triiodothyronine, serum thyroglobulin and serum thyroglobulin antibodies. Both groups became euthyroid within two weeks. No statistically significant difference in the values for the clinical score or for any of the laboratory parameters measured was found between propranolol- and the placebo-treated patients. It is concluded that propranolol has no beneficial effect on tiamazol-treated hyperthyroid patients.
25例新诊断的甲状腺毒症患者参与了一项关于普萘洛尔在甲巯咪唑治疗期间附加作用的双盲研究。在试验期间,通过定期评估临床评分(克鲁克斯 - 韦恩指数)、游离甲状腺素指数、血清三碘甲状腺原氨酸、血清反三碘甲状腺原氨酸、血清甲状腺球蛋白和血清甲状腺球蛋白抗体来确定治疗效果。两组均在两周内恢复甲状腺功能正常。在接受普萘洛尔治疗和接受安慰剂治疗的患者之间,临床评分或所测量的任何实验室参数值均未发现有统计学显著差异。得出的结论是,普萘洛尔对接受甲巯咪唑治疗的甲状腺功能亢进患者没有有益作用。